Results 181 to 190 of about 1,678,722 (395)

Expert Perspective: Diagnosis and Treatment of Castleman Disease

open access: yesArthritis &Rheumatology, EarlyView.
Castleman disease (CD) is a major diagnostic challenge for rheumatologists. Unicentric CD (UCD) involves one enlarged lymph node region, whereas multicentric CD (MCD) involves multiple enlarged lymph node regions. Both UCD and MCD may exhibit a wide range of symptoms that overlap with other immune‐mediated conditions.
Luke Y. C. Chen   +2 more
wiley   +1 more source

Nonbacterial Thrombotic Endocarditis [PDF]

open access: yes, 2020
Atallah, Rami   +5 more
core   +2 more sources

B cells and systemic sclerosis interstitial lung disease

open access: yesArthritis &Rheumatology, Accepted Article.
Interstitial lung disease is an important complication of systemic sclerosis (SSc‐ILD) with high mortality and morbidity. Recent clinical studies in SSc‐ILD have led to FDA‐approved therapies in SSc‐ILD. Importantly, evidence from these studies has been extrapolated to guide management of interstitial lung diseases of other systemic autoimmune ...
Nina Goldman   +2 more
wiley   +1 more source

Leveraging artificial intelligence for prediction of pulmonary hemorrhage in preterm infants. [PDF]

open access: yesJ Perinatol
Aly H   +5 more
europepmc   +1 more source

Hydralazine-Associated Vasculitis and Pulmonary Hemorrhage. [PDF]

open access: yesCureus, 2023
Strubchevska K   +3 more
europepmc   +1 more source

Massive pulmonary hemorrhage in polyarteritis nodosa(PN); Report of a case.

open access: bronze, 1990
Shinichi Uchida   +7 more
openalex   +2 more sources

Pulmonary Hemorrhage After Percutaneous Coronary Intervention With Abciximab Therapy [PDF]

open access: bronze, 2002
Rak Kyeong Choi   +4 more
openalex   +1 more source

Comparative efficacy and safety of anakinra and canakinumab in patients with VEXAS syndrome – an international multicenter study

open access: yesArthritis &Rheumatology, Accepted Article.
Objectives The aim of this study was to compare differences in clinical response, drug survival, and adverse event rates between anakinra and canakinumab in VEXAS syndrome. Methods This multicenter international study includes VEXAS patients from France, Israel, and Italy treated with IL1 inhibition (IL1i).
Tali Eviatar   +35 more
wiley   +1 more source

Home - About - Disclaimer - Privacy